Magnetic Resonance Imaging Study of Cognitive-Behavior Therapy for Major Depressive Disorder

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01460212

Enrollment

Registered

2011-10-26

Start date

2011-12-31

Completion date

2015-10-31

Last updated

2014-09-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major Depressive Disorder

Keywords

Cognitive-Behavior Therapy, Magnetic Resonance Imaging, major depressive disorder

Brief summary

Study hypothesis: psychotherapy and SSRI treatment effect in different brain way: psychotherapy in up to down way and SSRI in down to up way. The investigators will explore this hypothesis in major depressive disorder outpatients with Magnetic Resonance Imaging analysis in this study. Patients in different groups will be treated by psychotherapy or SSRI treatment. They will all be checked with Magnetic Resonance Imaging pro and after 12 weeks of treatment.

Detailed description

Patients meeting the inclusion criteria undergo an examination that included a diagnostic interview, vision test, and psychophysiological measures. Participants then undergo the baseline fMRI scan within 48 hours, after that, they will receive psychotherapy or SSRI treatment.and returned the scan once they completed the therapy.

Interventions

DRUGSSRI antidepressants

SSRI antidepressants are Selective serotonin reuptake inhibitors. They include fluoxetine (Prozac); sertraline (Zoloft); paroxetine (Paxil); citalopram (Celexa) ;escitalopram (Lexapro) and fluvoxamine (Luvox). It will be chosen according to special condition of every patient.

BEHAVIORALCognitive-Behavior Therapy

The essence of CBT is a learning process through which an appropriate pattern in cognitive and behavioral could be learn and stored as memory

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

20 Years to 50 Years

Healthy volunteers

Yes

Inclusion criteria

* meet SCID -Ⅰ/P major depressive disorder diagnosis; * Right handedness; * good visual acuity.

Exclusion criteria

* neurological disease ; * serious physical illness (e.g. heart, lung, liver, kidney or blood system disease); * with other mental disorder; * psychotic symptoms * personality disorders; * pregnancy; * suicidal risk; * treatment by antidepressants or other psychotropic medications within 6 months prior to the start of the trial; * with contraindication for MRI

Design outcomes

Primary

Measure	Time frame	Description
Hamilton Rating Scale for Depression (HAMD)	an expected average of 6 months	The 24-item version of the Hamilton Rating Scale for Depression (HAMD; Hamilton, 1960) will be used for measuring severity of depressive symptoms. Minimum and maximum possible values are respectively 0 and 78. Lower scores show more mild depression.

Secondary

Measure	Time frame
Magnetic Resonance Imaging	an expected average of 6 months

Countries

China

Contacts

Primary ContactChun Wang, doctor

fm51109@163.com86 15850566376

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026